Login to Your Account

Heptares $21M Series B Paves Way for Phase I in CNS Disorders

By Nuala Moran
Staff Writer

Wednesday, June 26, 2013
LONDON – Heptares Ltd. has raised $21 million in a Series B funding co-led by the Stanley Family Foundation, one of the leading foundations investing in neuroscience diseases. The new funding comes as Heptares is preparing to take its lead program, a first-in-class selective M1 muscarinic receptor agonist into a Phase I trial later this year, paving the way for the product to be developed as a treatment for cognitive impairment in schizophrenia and Alzheimer's disease.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription